Ezrin and Radixin Differentially Modulate Cell Surface Expression of Programmed Death Ligand-1 in Human Pancreatic Ductal Adenocarcinoma KP-2 Cells

Immune checkpoint blockade (ICB) therapies, such as immune checkpoint inhibitors against programmed death ligand-1 (PD-L1), have not been successful in treating patients with pancreatic ductal adenocarcinoma (PDAC). Despite the critical role of PD-L1 in various types of cancers, the regulatory mecha...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Immuno
المؤلفون الرئيسيون:	Takuro Kobori, Rina Doukuni, Honami Ishikawa, Yui Ito, Rie Okada, Chihiro Tanaka, Mayuka Tameishi, Yoko Urashima, Takuya Ito, Tokio Obata
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2022-01-01
الموضوعات:	programmed death ligand-1 ezrin radixin moesin pancreatic ductal adenocarcinoma immune checkpoint blockade
الوصول للمادة أونلاين:	https://www.mdpi.com/2673-5601/2/1/6